Bolt Biotherapeutics Inc.

0.47
-0.01 (-2.57%)
At close: Feb 10, 2025, 3:58 PM
0.47
-0.21%
After-hours Feb 10, 2025, 07:30 PM EST
undefined%
Bid 0.49
Market Cap 17.84M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.71
PE Ratio (ttm) -0.27
Forward PE n/a
Analyst Hold
Ask 0.53
Volume 84,513
Avg. Volume (20D) 163,153
Open 0.47
Previous Close 0.48
Day's Range 0.46 - 0.48
52-Week Range 0.46 - 1.56
Beta undefined

About BOLT

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for col...

Industry Biotechnology
Sector Healthcare
IPO Date Feb 5, 2021
Employees 100
Stock Exchange NASDAQ
Ticker Symbol BOLT

Analyst Forecast

According to 5 analyst ratings, the average rating for BOLT stock is "Hold." The 12-month stock price forecast is $1.25, which is an increase of 168.24% from the latest price.

Buy 0.00%
Hold 100.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Bolt Biotherapeutics Inc. is scheduled to release its earnings on Mar 20, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
9 months ago
-37.12%
Bolt Biotherapeutics shares are trading lower afte... Unlock content with Pro Subscription
9 months ago
-0.75%
Bolt Biotherapeutics shares are trading lower. The company reported Q1 financial results.